91,335 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 91,335 shares of the company’s stock, valued at approximately $1,797,000. Hsbc Holdings PLC owned about 0.08% of 10x Genomics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its position in shares of 10x Genomics by 48.2% in the second quarter. ARK Investment Management LLC now owns 9,313,763 shares of the company’s stock valued at $181,153,000 after purchasing an additional 3,029,951 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in 10x Genomics by 69.6% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock valued at $119,483,000 after buying an additional 2,521,289 shares in the last quarter. Venrock Management VI LLC bought a new position in 10x Genomics during the 4th quarter worth $117,894,000. Nikko Asset Management Americas Inc. lifted its holdings in shares of 10x Genomics by 58.6% during the first quarter. Nikko Asset Management Americas Inc. now owns 3,621,778 shares of the company’s stock worth $135,780,000 after buying an additional 1,338,248 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of 10x Genomics in the fourth quarter valued at about $36,262,000. 84.68% of the stock is owned by institutional investors.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $22.30 on Friday. The company’s 50 day moving average price is $21.31 and its two-hundred day moving average price is $24.82. The firm has a market capitalization of $2.69 billion, a P/E ratio of -10.00 and a beta of 1.85. 10x Genomics, Inc. has a fifty-two week low of $15.28 and a fifty-two week high of $57.90.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.15. 10x Genomics had a negative return on equity of 28.23% and a negative net margin of 37.90%. The company had revenue of $153.10 million for the quarter, compared to the consensus estimate of $150.90 million. On average, analysts expect that 10x Genomics, Inc. will post -1.32 earnings per share for the current year.

Analyst Ratings Changes

TXG has been the subject of a number of recent research reports. Wolfe Research reissued a “peer perform” rating on shares of 10x Genomics in a report on Thursday, June 27th. UBS Group reduced their price target on 10x Genomics from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 13th. JPMorgan Chase & Co. downgraded 10x Genomics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $40.00 to $20.00 in a research report on Thursday, July 18th. Bank of America decreased their price target on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating on the stock in a research report on Thursday, July 18th. Finally, Jefferies Financial Group raised shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of “Moderate Buy” and an average price target of $31.60.

Insider Activity

In related news, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the sale, the insider now directly owns 345,704 shares in the company, valued at approximately $7,788,711.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the transaction, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Justin J. Mcanear sold 2,961 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares in the company, valued at approximately $3,227,242.26. The disclosure for this sale can be found here. Insiders sold 14,061 shares of company stock valued at $316,794 over the last quarter. 10.03% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.